Regenerative
medicine has been
described as the
ultimate therapeutic
procedure for the
repair of tissues.
The
transplant
material
(cultured
corneal
epithelial
cell
sheets)
for
the
repair
of
the
corneal
epithelium,
for
which
we
are
currently
making
concerted
efforts
to
commercialize,
is
a "live
transplant
material" in
which
epithelial
cells
are
cultured
on
collagen
sheets
obtained
from
amniotic
membrane.
At
the
Department
of
Ophthalmology,
Kyoto
Prefectural
University
of
Medicine
(Professor
Shigeru
Kinoshita),
the
originator
of
this
technique,
numerous
patients
have
already
had
their
sight
restored
through
the
use
of
this
material.
Together
with
the
Kyoto
Prefectural
University
of
Medicine
and
other
research
specialists
in
regenerative
medicine,
we
are
striving
to
develop
a variety
of
products,
foremost
the
one
referred
to
above,
and
to
achieve
a higher
QOL
for
the
many
patients
suffering
from
refractory
disorders.
Meanwhile,
in
the
pharmaceutical
industry,
where
considerable
time
and
funds
are
required
for
product
development,
understanding
investors
have
backed
our
efforts.
A bioventure
company
that
enjoys
such
a fortunate
environment
as
ours
on
both
the
technology
and
management
fronts
is
a rarity,
for
which
the
directors
and
officers
are
all
sincerely
appreciative.
At
the
end
of
2003,
we
settled
into
the
Kobe
Medical
Industry
City,
Japan's
regenerative
medicine
base,
and
constructed
a pilot
plant
in
the
Kobe
International
Business
Center.
This
relocation
has
helped
accelerate
our
research
and
development
activities
while
also
facilitating
access
to
the
great
variety
of
support
in
the
Kobe
Medical
Industry
City.
In
a concerted
effort
from
all
those
involved,
we
will
strive
for
the
best
possible
commercial
application
of
research
outcomes
and
future
product
development,
and
relentlessly
pursue
novel
technologies
and
innovative
products.
We
promise
to
continue
developing
and
delivering
products
that
we
know
will
be
of
great
benefit.
It
is
my
greatest
hope
that
we
will
continue
to
benefit
from
the
support
and
encouragement
of
those
who
place
their
trust
in
us.
Akira Kitagawa, Ph.D.
President and Chief Exective Officer
|